Characterization of the Pharmaceutical Risk-Sharing Arrangement Process in Catalonia

Anna Reyes-Travé, Laura Guarga-Solé, Marta Roig-Izquierdo (), Enrique Alonso-Pérez, Ana Clopés-Estela and Joaquín Delgadillo-Duarte
Additional contact information
Anna Reyes-Travé: Servei Català de la Salut (CatSalut)
Laura Guarga-Solé: Servei Català de la Salut (CatSalut)
Marta Roig-Izquierdo: Servei Català de la Salut (CatSalut)
Enrique Alonso-Pérez: Servei Català de la Salut (CatSalut)
Ana Clopés-Estela: Institut Català d’Oncologia (ICO)
Joaquín Delgadillo-Duarte: Servei Català de la Salut (CatSalut)

PharmacoEconomics, 2021, vol. 39, issue 9, No 1, 973-982

Abstract: Abstract Pharmaceutical risk-sharing arrangements have emerged as a reasonable tool to promote sustainable access to innovative medicines with uncertain clinical evidence and/or economic impact from the payer perspective. These funding mechanisms pose an alternative option to the traditional fixed-price methods and are intended to align the price of medication with the value delivered in treating patients, balancing clinical need with affordability in the face of increasing therapeutic innovation and ever-tight budgets. The Catalan Health Service (CatSalut) has set up a systematic, traceable, and transparent methodology for the design and implementation of risk-sharing arrangements and 15 of such access schemes have been successfully implemented until December 2019. Our experience has acknowledged the need for a robust study design, appropriate financial, technical, and administrative resources, and strong stakeholder commitment and communication as critical to the success of risk-sharing arrangements. While the experience in Catalonia has been positive and has served to highlight the potential of such schemes in tackling public health policy concerns, this exchange can often be undermined by the lack of transparency surrounding risk-sharing arrangements and the fact that the literature related to their methodology, implementation, and impact is scarce. Further studies should be conducted and shared to address this obstacle.

Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40273-021-01046-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:39:y:2021:i:9:d:10.1007_s40273-021-01046-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-021-01046-1

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().